Gedeon Richter Plc.

Introduction
Trading data
Financials
Shareholders, management
Publications
Product features

Full Name

Chemical Works of Gedeon Richter Plc.

Short name

Gedeon Richter Plc.

Sector

Pharmaceuticals

Contact

HU-1103 Budapest, Gyömrői út 19-21.

Phone: +36-1-431-4027

Fax: -

Web: www.gedeonrichter.com

Investor Relations

Róbert Réthy

E-mail: rethyr@richter.hu

Phone: +36-1-431-5680

Fax: -

Auditor

Deloitte Co. Ltd.

Business activity

Founded in 1901 by Gedeon Richter, the plant was transformed into a business entity in 1923. Since 1997, it has been the largest domestic drug manufacturer. Its main activity is the manufacturing and distribution of active ingredients and generic pharmaceuticals. Richter has now grown into a multinational company of the Central and Eastern European region. Due to a market network unique in the region and covering five continents, the company s products are available in nearly one hundred countries worldwide. Also unique among Hungarian companies is its network of market interests, comprising the member states of the European Union, the United States of America, the CIS states, Japan and the Eastern region. It operates an extensive marketing and distribution network in Hungary, the CIS states and Eastern Europe.

Listed securities of the issuer

Name	Ticker	ISIN
RICHTER 2031 HUF Bond	RICHTER31	HU0000360441
Richter Gedeon share	RICHTER	HU0000123096

Download Trading Data

Show trades

Basic Information
Ticker	RICHTER
ISIN	HU0000123096
Date of listing	09 Nov 1994
Currency of trading	HUF
Face Value	100 HUF
Number of securities listed	186,374,860
Market Capitalisation (HUF million)	1,992,347

> Split (S)/Reverse split (R)
11 Jul 2013	S (1 : 10)

P/BV
P/BV*	1.6226

* Calculating based on the capitalisation of the actual series only

Performance

* annualized yield

Key annual data

audited, consolidated, IFRS; Business Year: January 1 - December 31

	2022¹	2023²
	(million HUF)	(million HUF)
Total revenues	802,755	805,158
Operating Profit (EBIT)	153,555	189,364
Net income from financial activities	5,958	-23,958
Profit before tax	165,663	171,540
Profit after tax	157,255	160,651
Dividend per (ordinary) share	391.32 HUF	431.98 HUF
Fixed Assets	764,519	826,304
Total liabilities	279,937	218,636
Share capital	18,638	18,636
Shareholders equity	1,060,352	1,142,581
Total assets	1,340,289	1,361,217
Number of employees (at business year end)	12,167	11,603

(1) Audited, consolidated, in compliance with IFRS (Business Year: January 1 - December 31)

(2) audited, consolidated, IFRS; Business Year: January 1 - December 31

Download in Excel format Latest Annual Report

Selected financial ratios

Ratios are based on data submitted by the company

	2022	2023
Equity Ratio	0.26	0.19
Return on assets (ROA)	0.15	0.14
Return on equity (ROE)	0.12	0.12

Download in Excel format

Mid-year reports

non-audited, consolidated, IFRS; Business Year: January 1 - December 31

Key P&L Figures	Jan 2023 - Sep 2023¹	Jan 2024 - Sep 2024¹
	(million HUF)	(million HUF)
Net sales	601,980	636,423
Operating profit (EBIT)	144,411	190,199
Net income from financial activities	-18,437	5,808
Profit before tax	130,249	202,521
Profit after tax	123,749	175,918

Key Balance Sheet Items	30 Sep 2023	30 Sep 2024
	(million HUF)	(million HUF)
Fixed Assets	805,187	914,862
Intangible Assets	267,844	333,252
Tangible assets	332,672	368,292
Invested financial assets	183,426	176,853
Current Assets	552,247	571,870
Inventory	181,342	207,056
Total assets	1,357,434	1,486,732
Shareholders equity	1,095,004	1,227,898
Share capital	18,638	18,638
Long-term liabilities	104,170	117,880
Short-term liabilities	158,260	140,954
Total liabilities and shareholders equity	1,357,434	1,486,732

(1) non-audited, consolidated, IFRS; Business Year: January 1 - December 31

Download in Excel format Latest half-yearly/quarterly report Latest interim management statement

Shareholders exceeding 5% stake with respect to the listed series
Name	Shareholding (%)	Share piece
Maecenas Universitatis Corvini Alapítvány	10.00	18,637,486
Mathias Corvinus Collegium Alapítvány	10.00	18,637,486
Nemzeti Egészségügyi és Orvosképzésért Alapítvány	5.25	9,777,658
FMR LLC	5.07	9,457,941
Free Float: 69.68%	Last update: 30 Aug 2024
Note: When determining the Free Float for a particular series, all the securities of the company shall be regarded to be publicly held other than (i) the stock of securities held by holders with direct holdings of more than 5% of the total number of securities, (ii) securities in the possession of custodians, provided the certificate available to the custodian verifies that the particular person holds more than 5% of the total number of securities outstanding belonging to the series. The value of the free float is based on the data provided by the issuer.

Management
Management Board	BOGSCH Erik (Honorary President), ORBÁN Gábor, Dr. PINTÉRNÉ dr. HARDY Ilona, Prof. Dr. VIZI E. Szilveszter (President of the Board), Dr. PANDURICS Anett (Deputy President of the Board), SZÉCSÉNYI Bálint, Dr. CSERHÁTI Péter, Dr. ÁCS Nándor, HAMECZ István, BALOGH Gabriella, SZEPESI Balázs, NÉMETH Lászlóné
Management	ORBÁN Gábor (CEO), Dr. GREINER István (Research and Development Director), HORVÁTH Tibor (Commercial Director), ERDEI Katalin (Director of Human Resources), SZOLYÁK Tamás (Director, Global Regulatory Science and Portfolio Managment), SZÉNÁSI Attila (Director of Production ang Logistic activities)
Supervisory Board	Dr. BEDROS Jonathán Róbert, Dr. PAVLIK Lívia, Dale André MARTIN, Dr. GÁL Krisztina, SALLAI Ferenc
	Last update: 26 Apr 2024

Publication	News
02 Dec 2024 13:10	Composition of share capital of the Company and number of voting rights attached to the shares on 30 November, 2024
12 Nov 2024 10:40	Subsidiaries transactions Q3 2024
12 Nov 2024 06:00	Company presentation 9 months to September 2024
31 Oct 2024 09:15	Composition of share capital of the Company and number of voting rights attached to the shares on 31 October, 2024
24 Oct 2024 17:30	AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
09 Oct 2024 08:00	Bio-Thera and Richter Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, for EU countries, UK, Switzerland and other selected countries
01 Oct 2024 11:38	Composition of share capital of the Company and number of voting rights attached to the shares on 30 September, 2024
24 Sep 2024 08:00	Approval for Alyssa® combination tablets (FSN-013), an Estetrol-based drug in Japan
19 Sep 2024 12:25	Transactions with Treasury Shares
16 Sep 2024 08:00	Inauguration of the new cGMP biopharmaceuticals facility in Bovenau, Germany

Publication	Report
26 Apr 2024 15:20	Annual Report approved by Gedeon Richter Plc.'s Annual General Meeting on April 25, 2024 (ZIP)
06 Aug 2024 06:00	Gedeon Richter Plc. - 2024 Half-yearly Report
26 Apr 2024 15:11	Gedeon Richter Plc.'s Corporate Governance Report from year 2023

Publication	Articles of Association
31 May 2024 12:36	Statutes

Publication	Voting rights, registered capital
02 Dec 2024 13:10	Composition of share capital of the Company and number of voting rights attached to the shares on 30 November, 2024

Publication	Corporate Action Timetable
19 Dec 2023 15:00	Corporate Action Timetable 2024

Further publications by the issuer Further publications of issuers

Name of security	Richter Gedeon share
Issuer	Chemical Works of Gedeon Richter Plc.
Equity class	Ordinary share
Type of security	Registered
Form of security	Dematerialised
Code of security (ISIN)	HU0000123096
Ticker symbol	RICHTER
Face value	100 HUF
Number of securities listed	186,374,860
Rights to dividends	Full year
Listing date	09 Nov 1994
First Trading Day	09 Nov 1994
Market	Prime
Trading Unit
Currency of trading	HUF
Trading time
Listing price	1,330